TSE:4502Pharmaceuticals
Takeda’s R&D Shakeup And Leadership Transition Might Change The Case For Investing In Takeda Pharmaceutical (TSE:4502)
In early April 2026, Takeda moved to end its 2018 co-development agreement with Denali Therapeutics for DNL593 and continued to reshape its portfolio through late-stage assets like zasocitinib and the priority-reviewed rusfertide, while also transferring global rights to schizophrenia candidate balipodect to Axsome Therapeutics.
This combination of collaboration exits, asset sales, advancing Phase 3 programs, and an upcoming CEO and board transition marks a meaningful refocusing of Takeda’s...